deferoxamine has been researched along with Arthralgia in 6 studies
Deferoxamine: Natural product isolated from Streptomyces pilosus. It forms iron complexes and is used as a chelating agent, particularly in the mesylate form.
desferrioxamine B : An acyclic desferrioxamine that is butanedioic acid in which one of the carboxy groups undergoes formal condensation with the primary amino group of N-(5-aminopentyl)-N-hydroxyacetamide and the second carboxy group undergoes formal condensation with the hydroxyamino group of N(1)-(5-aminopentyl)-N(1)-hydroxy-N(4)-[5-(hydroxyamino)pentyl]butanediamide. It is a siderophore native to Streptomyces pilosus biosynthesised by the DesABCD enzyme cluster as a high affinity Fe(III) chelator.
Arthralgia: Pain in the joint.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The role of the orally active iron (Fe) chelator deferiprone in the treatment of beta-thalassemia remains a controversial subject." | 8.81 | The controversial role of deferiprone in the treatment of thalassemia. ( Richardson, DR, 2001) |
| "The most frequent side effects were joint pain, stiffness or swelling in 6 patients (35." | 6.69 | Efficacy and side effects of deferiprone (L1) in thalassemia patients not compliant with desferrioxamine. ( Chamoun, FM; Khoriaty, AI; Koussa, S; Mourad, FH; Neeman, R; Saad, MA; Taher, A, 1999) |
| "The role of the orally active iron (Fe) chelator deferiprone in the treatment of beta-thalassemia remains a controversial subject." | 4.81 | The controversial role of deferiprone in the treatment of thalassemia. ( Richardson, DR, 2001) |
| "Neutropenia and agranulocytosis were also detected, suggesting needing of strict hematological control." | 2.80 | Deferiprone versus deferoxamine in thalassemia intermedia: Results from a 5-year long-term Italian multicenter randomized clinical trial. ( Calvaruso, G; Colletta, G; Di Maggio, R; Gerardi, C; Lai, E; Maggio, A; Pitrolo, L; Quota, A; Rigoli, LC; Sacco, M; Vitrano, A, 2015) |
| " We conclude that the short-term use of L1, with or without DFO, was safe and efficacious in our Chinese patient cohort." | 2.72 | A randomized controlled study evaluating the safety and efficacy of deferiprone treatment in thalassemia major patients from Hong Kong. ( Chan, GC; Chik, KW; Ha, SY; Lam, CW; Lee, AC; Ling, SC; Luk, CW; Ng, IO, 2006) |
| "The most frequent side effects were joint pain, stiffness or swelling in 6 patients (35." | 2.69 | Efficacy and side effects of deferiprone (L1) in thalassemia patients not compliant with desferrioxamine. ( Chamoun, FM; Khoriaty, AI; Koussa, S; Mourad, FH; Neeman, R; Saad, MA; Taher, A, 1999) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (16.67) | 18.2507 |
| 2000's | 3 (50.00) | 29.6817 |
| 2010's | 2 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Calvaruso, G | 1 |
| Vitrano, A | 1 |
| Di Maggio, R | 1 |
| Lai, E | 1 |
| Colletta, G | 1 |
| Quota, A | 1 |
| Gerardi, C | 1 |
| Rigoli, LC | 1 |
| Sacco, M | 1 |
| Pitrolo, L | 1 |
| Maggio, A | 1 |
| Balocco, M | 1 |
| Carrara, P | 1 |
| Pinto, V | 1 |
| Forni, GL | 1 |
| Ha, SY | 1 |
| Chik, KW | 1 |
| Ling, SC | 1 |
| Lee, AC | 1 |
| Luk, CW | 1 |
| Lam, CW | 1 |
| Ng, IO | 1 |
| Chan, GC | 1 |
| Tanner, MA | 1 |
| Galanello, R | 1 |
| Dessi, C | 1 |
| Smith, GC | 1 |
| Westwood, MA | 1 |
| Agus, A | 1 |
| Roughton, M | 1 |
| Assomull, R | 1 |
| Nair, SV | 1 |
| Walker, JM | 1 |
| Pennell, DJ | 1 |
| Taher, A | 1 |
| Chamoun, FM | 1 |
| Koussa, S | 1 |
| Saad, MA | 1 |
| Khoriaty, AI | 1 |
| Neeman, R | 1 |
| Mourad, FH | 1 |
| Richardson, DR | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Iron-mediated Vascular Disease in Sickle Cell Disease.[NCT01239901] | 150 participants (Actual) | Observational | 2009-12-31 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for deferoxamine and Arthralgia
| Article | Year |
|---|---|
The controversial role of deferiprone in the treatment of thalassemia.
Topics: Agranulocytosis; Arthralgia; Clinical Trials as Topic; Deferiprone; Deferoxamine; Drug Therapy, Comb | 2001 |
4 trials available for deferoxamine and Arthralgia
| Article | Year |
|---|---|
Deferiprone versus deferoxamine in thalassemia intermedia: Results from a 5-year long-term Italian multicenter randomized clinical trial.
Topics: Adult; Agranulocytosis; Arthralgia; beta-Thalassemia; Chelation Therapy; Deferiprone; Deferoxamine; | 2015 |
A randomized controlled study evaluating the safety and efficacy of deferiprone treatment in thalassemia major patients from Hong Kong.
Topics: Adolescent; Adult; Arthralgia; beta-Thalassemia; Biopsy, Needle; Chelation Therapy; Child; Combined | 2006 |
A randomized, placebo-controlled, double-blind trial of the effect of combined therapy with deferoxamine and deferiprone on myocardial iron in thalassemia major using cardiovascular magnetic resonance.
Topics: Adult; Agranulocytosis; Arthralgia; beta-Thalassemia; Chelation Therapy; Deferiprone; Deferoxamine; | 2007 |
Efficacy and side effects of deferiprone (L1) in thalassemia patients not compliant with desferrioxamine.
Topics: Adolescent; Adult; Arthralgia; Child; Deferiprone; Deferoxamine; Female; Ferritins; Follow-Up Studie | 1999 |
1 other study available for deferoxamine and Arthralgia
| Article | Year |
|---|---|
Daily alternating deferasirox and deferiprone therapy for "hard-to-chelate" beta-thalassemia major patients.
Topics: Administration, Oral; Arthralgia; Benzoates; beta-Thalassemia; Chelation Therapy; Deferasirox; Defer | 2010 |